Information on EC 5.3.99.3 - prostaglandin-E synthase

New: Word Map on EC 5.3.99.3
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Bilateria

EC NUMBER
COMMENTARY hide
5.3.99.3
-
RECOMMENDED NAME
GeneOntology No.
prostaglandin-E synthase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
(13E)-(15S)-15-hydroxy-9-oxoprosta-10,13-dienoate = (13E)-(15S)-15-hydroxy-9-oxoprosta-11,13-dienoate
show the reaction diagram
-
-
-
-
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate = (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
intramolecular oxidation
-
-
-
-
isomerization
reduction
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
arachidonic acid metabolism
-
-
Arachidonic acid metabolism
-
-
C20 prostanoid biosynthesis
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
(5Z,13E)-(15S)-9alpha,11alpha-Epidioxy-15-hydroxyprosta-5,13-dienoate E-isomerase
Brings about the opening of the epidioxy bridge. Requires glutathione.
CAS REGISTRY NUMBER
COMMENTARY hide
52227-79-9
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
zebrafish
SwissProt
Manually annotated by BRENDA team
rhesus monkey
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
evolution
malfunction
metabolism
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-9a,11a-epidioxy-15-hydroxyprosta-5,13-dienoate + GSH
(5Z,13E)-(15S)-11a,15-dihydroxyprosta-5,13-dienoate + GSSG
show the reaction diagram
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + GSH
(5Z,13E)-(15S)-11alpha,15-dihydroxyprosta-5,13-dienoate + GSSG
show the reaction diagram
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + reduced glutathione
(5Z,13E)-(15S)-11alpha,15-dihydroxyprosta-5,13-dienoate + oxidized glutathione
show the reaction diagram
-
i.e. prostaglandin H2
i.e. prostaglandin E2
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
1-chloro-2,4-dinitrobenzene + GSH
?
show the reaction diagram
-
glutathione S-transferase activity
-
?
15-hydroperoxy-prostaglandin E2 + GSH
prostaglandin E2 + GSSG
show the reaction diagram
-
-
-
?
5-hydroperoxyeicosatetraenoic acid + 2 GSH
5-hydroxyeicosatetraenoic acid + GSSG + H2O
show the reaction diagram
-
-
-
?
cumene hydroperoxide + 2 GSH
cumene hydroxide + GSSG + H2O
show the reaction diagram
-
-
-
?
Prostaglandin G1
15-Hydroperoxy-prostaglandin E1
show the reaction diagram
-
at 50% of the activity relative to prostaglandin H
major product
-
Prostaglandin G2
15-Hydroperoxy-prostaglandin E2
show the reaction diagram
prostaglandin G2 + GSH
15-hydroperoxy-prostaglandine E2 + GSSG
show the reaction diagram
-
-
-
?
Prostaglandin H
?
show the reaction diagram
-
involved in prostaglandin synthesis, which in the case of prostaglandin E is likely to be associated with the subversion or suppression of host immunity
-
-
-
Prostaglandin H1
Prostaglandin E1
show the reaction diagram
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
Prostaglandin H
?
show the reaction diagram
-
involved in prostaglandin synthesis, which in the case of prostaglandin E is likely to be associated with the subversion or suppression of host immunity
-
-
-
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
glutathione
heme
-
crystallization data of red-coloured protein purified after growth of recombinant Escherichia coli in LB medium containing delta-aminolevulinate and Fe(NO3)3. Heme is complexed with bound glutathione forming a S-Fe coordination bond with no polar interaction with enzyme. Heme dissociation constant is 0.00053 mM
additional information
-
mutants R126A/Q possess glutathione-dependent reductase activity
-
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1-benzyl-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)acetic acid
-
35% inhibition at 0.001 mM
(2E)-2-(2,5-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]benzylidene)hexanoic acid
-
-
(2E)-2-(2,5-bis[[4-(trifluoromethyl)benzyl]oxy]benzylidene)hexanoic acid
-
55.1% residual activity at 0.01 mM
(2E)-2-[2,5-bis(2-cyclohexylethoxy)benzylidene]hexanoic acid
-
-
(2E)-2-[2,5-bis(2-phenylethoxy)benzylidene]hexanoic acid
-
-
(2E)-2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzylidene]hexanoic acid
-
28.3% residual activity at 0.01 mM
(2E)-2-[5-(2-cyclohexylethoxy)-2-[[4-(trifluoromethyl)benzyl]oxy]benzylidene]hexanoic acid
-
74% residual activity at 0.01 mM
(2R)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
(2S)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
(4-dodecanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)acetic acid
-
22% inhibition at 0.001 mM
(4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)acetic acid
-
17% inhibition at 0.001 mM
(4E)-4-[2-(3-bromophenyl)hydrazin-1-ylidene]-1-ethanethioyl-3-methyl-4,5-dihydro-1H-pyrazol-5-one
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(5,8-dihydronaphthalen-1-yl)acetic acid
-
-
([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)acetic acid
-
75.4% residual activity at 0.01 mM
1-benzyl-4-dodecanoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid
-
65% inhibition at 0.001 mM
1-[2-(2-methylphenyl)ethyl]-4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazole
-
90% residual activity at 0.03 mM
1-[4-[2-(2-carboxy-2-methylpropyl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-4-yl]-2-fluorophenyl]pyridinium
-
-
15-deoxy-DELTA12,14-prostaglandin J2
-
-
2(4-(3-biphenyloxypropoxy)phenylthio)hexanoic acid
-
-
2-(2,3-diphenethoxybenzylidene)hexanoic acid
-
-
2-(2-chloro-6-fluorophenyl)-4-(4-chlorophenyl)-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-(4-phenoxyphenyl)-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(2-phenylethyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylethynyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfonyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-[(E)-2-phenylethenyl]phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one
-
-
2-(3,5-diphenethoxybenzyl)hexanoic acid
-
-
2-(3,5-diphenethoxybenzylidene)hexanoic acid
-
-
2-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-imidazole
-
-
2-(4-dodecanoyl-3,5-dimethyl-1-phenylpyrrol-2-yl)acetic acid
-
23% inhibition at 0.001 mM
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
-
-
2-([4,6-bis[2-(4-cyanophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4,6-bis[2-(4-methoxyphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
63.7% residual activity at 0.01 mM
2-([4,6-bis[2-(4-methylphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4,6-bis[2-(4-nitrophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4,6-bis[2-(thiophen-3-yl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-chloro-6-[(4'-cyanobiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-chloro-6-[(5-methoxy-2-methylbiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-[(biphenyl-4-ylmethyl)amino]-6-chloropyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
88.3% residual activity at 0.01 mM
2-([4-[3-(2-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(3-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
59.1% residual activity at 0.01 mM
2-([4-[3-(3-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
58% residual activity at 0.01 mM
2-([4-[3-(4-chloro-2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(4-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-chloro-N-[3-(naphthalen-1-ylcarbamoyl)phenyl]benzamide
2-[(3,5-diphenethoxyphenyl)thio]hexanoic acid
-
-
2-[(4,6-bis[2-[4-(trifluoromethoxy)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
-
88.3% residual activity at 0.01 mM
2-[(4,6-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
-
-
2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid
-
-
2-[(4-[3-[2-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[3-[3-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[3-[3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[3-[4-chloro-3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]nonanoic acid
-
-
2-[2,3-bis(2-phenylethoxy)benzyl]hexanoic acid
-
-
2-[2,4-bis(2-phenylethoxy)benzyl]hexanoic acid
-
90.1% residual activity at 0.01 mM
2-[2,5-bis(2-phenylethoxy)benzyl]hexanoic acid
-
-
2-[2-(2-chloro-6-fluorophenyl)-4-[6-(phenylethynyl)pyridin-3-yl]-1H-imidazol-5-yl]ethanol
-
-
2-[3,4-bis(2-phenylethoxy)benzyl]hexanoic acid
-
-
2-[3,5-bis(2-phenylethoxy)phenoxy]hexanoic acid
-
-
2-[3-(aminooxy)-2,2-dimethyl-3-oxopropyl]-3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indole
-
IC50: 0.01 mM
2-[4-(4-bromophenyl)-1H-imidazol-2-yl]benzonitrile
-
-
2-[4-(4-chlorophenyl)-1H-imidazol-2-yl]-3-fluorobenzonitrile
-
-
2-[4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)phenyl]propan-2-ol
-
-
2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzyl]hexanoic acid
-
-
2-[6-(2-cyclopropylethoxy)-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid
-
licofelone, ML3000
2-[6-bromo-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[6-chloro-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[6-chloro-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[[4,6-bis(2-cycloheptylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
62.4% residual activity at 0.01 mM
2-[[4,6-bis(2-cyclohexylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(2-cyclopentylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
90% residual activity at 0.01 mM
2-[[4,6-bis(2-cyclopropylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]butanoic acid
-
-
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]octanoic acid
-
-
2-[[4,6-bis(3-methylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
54.5% residual activity at 0.01 mM
2-[[4,6-bis(3-phenylpropoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(4-phenylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(benzyloxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4-(3-phenoxypropoxy)phenyl]sulfanyl]hexanoic acid
-
81.9% residual activity at 0.01 mM
2-[[4-(biphenyl-4-ylamino)-6-chloropyrimidin-2-yl]sulfanyl]nonanoic acid
-
-
3,4-bis-(3-benzo[b]thiophen-3-yl-phenyl)-5-hydroxy-5H-furan-2-one
-
3-(1,3,5-trimethyl-4-octadecanoyl-1H-pyrrol-2-yl)propanoic acid
-
97% inhibition at 0.001 mM
3-(1,3,5-trimethyl-4-tetradecanoyl-1H-pyrrol-2-yl)propanoic acid
-
91% inhibition at 0.001 mM
3-(1-benzothiophen-2-yl)-2-bromo-5-hydroxycyclopent-2-en-1-one
-
-
3-(1-benzyl-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)propanoic acid
-
62% inhibition at 0.001 mM
3-(1-benzyl-4-dodecanoyl-5-methyl-3-phenylpyrrol-2-yl)propionic acid
-
64% inhibition at 0.001 mM
3-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazole
-
-
3-(4-dodecanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid
-
54% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)-N-(benzenesulfonyl)propanamide
-
77% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)-N-(methanesulfonyl)propanamide
-
52% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)propanamide
-
39% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)propanehydrazide
-
35% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)propanenitrile
-
22% inhibition at 0.001 mM
3-(4-dodecanoyl-1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)propanoic acid
-
90% inhibition at 0.001 mM
3-(4-dodecanoyl-3,5-dimethyl-1-phenylpyrrol-2-yl)propionic acid
-
65% inhibition at 0.001 mM
3-(4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)propanoic acid
-
38% inhibition at 0.001 mM
3-(4-hexadecanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid
-
97% inhibition at 0.001 mM
3-(naphthalen-1-ylamino)-6-nitrobenzo[d]isothiazole 1,1-dioxide
-
-
3-benzamidocarbazole
-
-
3-bromo-4-(4'-butyl-biphenyl-4-yl)-5-hydroxy-5H-furan-2-one
-
3-bromo-5-hydroxy-4-[1,1':4',1'']terphenyl-4-yl-5H-furan-2-one
-
3-[(5E)-3-(4-butylbenzyl)-1-(4-chlorobenzyl)-4-methylidene-5-[(2E)-4-methylpent-2-en-1-ylidene]-4,5-dihydro-1H-pyrrol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00029 mM
3-[1-(4-carbamoylbenzyl)-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
28% inhibition at 0.001 mM
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00025 mM
3-[1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0032 mM
3-[1-(4-chlorobenzyl)-3-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0011 mM
3-[1-(4-chlorobenzyl)-3-methyl-5-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00060 mM
3-[1-(4-chlorobenzyl)-3-methyl-7-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0043 mM
3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid
-
MK-886
3-[1-(4-chlorobenzyl)-4-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
78% inhibition at 0.001 mM
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenoxy-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00065 mM
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0064 mM
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-[(2-methylphenyl)carbonyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00090 mM
3-[1-(4-chlorobenzyl)-5-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000004 mM
3-[1-(4-chlorobenzyl)-5-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000008 mM
3-[1-(4-chlorobenzyl)-5-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000022 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000005 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000003 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-3'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000033 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-4'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000031 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-5-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-5-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
3-[1-(4-chlorobenzyl)-5-(3-fluoro-4-pyridin-3-ylphenyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000012 mM
3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0026 mM
3-[1-(4-chlorobenzyl)-5-[2-fluoro-2'-(phenylcarbonyl)biphenyl-4-yl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000006 mM
3-[1-(4-chlorobenzyl)-5-[3-fluoro-4-(pyrimidin-5-ylmethyl)phenyl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000032 mM
3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid
-
i.e. 3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid or FLAP, formerly designated L-663,536, a lipoxygenase inhibitor, IC50: 0.0016 mM
3-[3-(benzylsulfanyl)-1-(4-chlorobenzyl)-5-[4-[(4-chloro-2-fluorophenyl)ethynyl]phenyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
3-[3-(tert-butylsulfanyl)-1-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.01 mM
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-(3-phenylpropyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0032 mM
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-prop-2-en-1-yl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0067 mM
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.01 mM
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00026 mM
3-[4-(2'-acetyl-2-fluorobiphenyl-4-yl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[4-(4-butoxybenzoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl]propanoic acid
-
32% inhibition at 0.001 mM
3-[4-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[4-dodecanoyl-1-(4-hydroxybenzyl)-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
53% inhibition at 0.001 mM
3-[4-dodecanoyl-1-(4-methoxybenzyl)-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
72% inhibition at 0.001 mM
3-[4-dodecanoyl-3,5-dimethyl-1-(4-methylbenzyl)-1H-pyrrol-2-yl]propanoic acid
-
52% inhibition at 0.001 mM
3-[4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]propanoic acid
-
83.9% residual activity at 0.01 mM
3-[5-biphenyl-3-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00016 mM
3-[5-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000016 mM
3-[5-tert-butyl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00033 mM
4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
-
73.6% residual activity at 0.03 mM
4'-[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]biphenyl-3-ol
-
60.1% residual activity at 0.03 mM
4'-[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
-
89% residual activity at 0.03 mM
4'-[1-[2-(2-methylphenyl)ethyl]-1H-1,2,3-triazol-4-yl]biphenyl-4-amine
-
98.2% residual activity at 0.03 mM
4-(2'-[[2-chloro-5-(trifluoromethyl)phenoxy]methyl]biphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
91.9% residual activity at 0.03 mM
4-(2'-[[2-chloro-5-(trifluoromethyl)phenoxy]methyl]biphenyl-4-yl)-1-[2-(2-methylphenyl)ethyl]-1H-1,2,3-triazole
-
87.9% residual activity at 0.03 mM
4-(4'-butyl-biphenyl-4-yl)-3-(4-butyl-phenyl)-5-hydroxy-5H-furan-2-one
-
4-(4'-phenoxybiphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
88.7% residual activity at 0.03 mM
4-(4-benzylphenyl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
-
-
4-(4-chlorobenzyl)-2,6-bis[4-(trifluoromethoxy)phenyl]-4H-thieno[3,2-b]pyrrole
-
-
4-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)butanoic acid
-
70% inhibition at 0.001 mM
4-(biphenyl-4-yl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
-
-
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzamide
-
-
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzoic acid
-
-
4-dodecanoyl-1,3,5-trimethyl-1H-pyrrole-2-carboxylic acid
-
37% inhibition at 0.001 mM; 59% inhibition at 0.001 mM
4-dodecanoyl-3,5-dimethyl-1-phenylpyrrole-2-carboxylic acid
-
99% inhibition at 0.001 mM
4-dodecanoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid
-
62% inhibition at 0.001 mM
4-[(4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazol-1-yl)sulfonyl]benzoic acid
-
59.8% residual activity at 0.03 mM
4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
96.8% residual activity at 0.03 mM
4-[4-(phenanthren-9-yl)phenyl]-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
78.2% residual activity at 0.03 mM
4-[4-benzyl-1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-5-yl]benzaldehyde
-
72.1% residual activity at 0.03 mM
4-[[2-(2-carboxyethyl)-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-1-yl]methyl]benzoic acid
-
27% inhibition at 0.001 mM
4-[[4-(biphenyl-4-yl)-1H-1,2,3-triazol-1-yl]methyl]-3-nitrobenzoic acid
-
most efficient inhibitor of mPGES-1, 12% residual activity at 0.03 mM
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole
-
-
5-(4-bromophenyl)-3-(2-chloro-6-fluorophenyl)-1,2,4-oxadiazole
-
-
5-(4-cyclohexylphenyl)-1-[4-(1-methylethoxy)benzyl]-1H-indole-2-carboxylic acid
-
-
5-(4-tert-butylphenyl)-1-[4-(1-methylethoxy)benzyl]-1H-indole-2-carboxylic acid
-
-
5-(4-tert-butylphenyl)-3-[4-(1-methylethoxy)phenyl]-1-[4-[(1-methylethyl)amino]benzyl]-1H-indole-2-carboxylic acid
-
-
5-(dimethylamino)-N-[4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-yl]naphthalene-1-sulfonamide
-
85% residual activity at 0.03 mM
5-hydroxy-3-naphthalen-2-yl-4-(3-naphthalen-2-yl-phenyl)-5H-furan-2-one
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(1,3-thiazol-2-ylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohex-1-en-1-ylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohexylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclopropylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(pyridin-3-ylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-ethynylpyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(2-chlorophenyl)ethynyl]pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(3-chlorophenyl)ethynyl]pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(4-chlorophenyl)ethynyl]pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-5-methyl-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
5-[5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-(phenylethynyl)pyridine
-
-
5-[5-bromo-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
5-[5-chloro-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
6-nitro-3-(m-tolylamino) benzo[d]isothiazole 1,1-dioxide
-
i.e. JMC-7
6-nitro-N-phenyl-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
6-nitro-N-[3-(propan-2-yl)phenyl]-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
7-hydroxy-N,N'-bis(2,4,6-trimethylphenyl)naphthalene-1,3-disulfonamide
-
-
acetaminophen
-
-
aminomethyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
-
-
arachidonic acid
-
-
benzothiophene gamma-hydroxybutenolide
-
biarylimidazole
-
-
Bis(3-carboxy-4-nitrophenyl)disulfide
-
-
cysteinyl leukotriene LTC4
-
-
deoxy-prostaglandin J2
-
IC50: 0.0003 mM
dexamethasone
Diallyl disulfide-oxide
-
i.e. allicin
dyphylline
-
-
eicosapentaenoic acid
-
-
ethyl 2-([4-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propoxy]phenyl]sulfanyl)hexanoate
-
-
ethyl 2-([4-[3-(biphenyl-4-yloxy)propoxy]phenyl]sulfanyl)hexanoate
-
-
ethyl 2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoate
-
83.9% residual activity at 0.01 mM
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]nonanoate
-
-
geldanamycin
-
-
heme
heme is bound to the enzyme subunits and alters the enzyme catalytic specificity, overview. Heme is attached to the bound GSH by an iron-sulfur bond, but heme cannot bind to mPGES2 in the absence of GSH, other sulfhydryl compounds, such as DTT and 2-mercaptoethanol, are unable to promote heme binding to isozyme mPGES2. Bound heme is oxidized by H2O2, but it does not dissociate from mPGES2
HgCl2
-
-
imidazole
imidazole stacks on the bound heme and inhibits heme oxidation by H2O2, heme dissociation by DTT, and catalytic activity
Indocyanine green
indomethacin
iodoacetamide
-
-
iodoacetic acid
-
-
Iodosobenzoic acid
-
-
leukotriene C4
-
-
methyl 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoate
-
IC50: 0.0072 mM
methyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
-
-
methyl 4-[6-bromo-2-(2-chloro-6-fluorophenyl)-1H-phenanthro[9,10-d]imidazol-9-yl]but-3-ynoate
-
-
MK 886
MK-0886
-
0.002 mM, 50% inhibition
MK-886
MK886
-
-
N-(1,3-benzodioxol-4-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(2-methylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3,4-dimethoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-bromobenzyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-bromophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-chlorophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-tert-butylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(4-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(5-bromonaphthalen-1-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(6-nitro-1,1-dioxido-1,2-benzothiazol-3-yl)quinolin-5-amine
-
-
N-(biphenyl-3-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-[4-chloro-3-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-2-(trifluoromethyl)benzamide
-
-
NS-398
Oxacillin
-
-
p-hydroxymercuribenzoate
-
-
PCMB
-
-
PF-9184
resveratrol
-
-
SB-203580
-
blocks the association of cPGES with casein kinase II and Hsp90, as well as cPGES phosphorylation
SC-236
sulindac
-
-
sulindac sulfide
-
-
[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]methyl benzoate
-
76.1% residual activity at 0.03 mM
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl](phenyl)acetic acid
-
-
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]acetic acid
-
66.4% residual activity at 0.01 mM
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
17beta-estradiol
-
up-regulates PTGES mRNA and protein level
all-trans retinoic acid
-
ATRA
angiotension II
-
angiotension II infusion induces mRNA expression of mPGES-1, mPGES-2 and cytosolic PGE synthase
-
bradykinin
-
-
captoprylsulfobetaine
-
10 mM, 2.6fold activation
diheptanoylphosphatidylcholine
-
2.2 mM, 4.8fold activation
Dihydrolipoic acid
-
-
dithiothreitol
epigallocatechin gallate
-
enhances COX-2 and isoform mPGES-1 gene expression and production of prostaglandin E2. Induction of mPGES-1 is mediated by active ERK1/2MAP kinases and early growth response gene 1
glutathione
Hsp90
-
maximal activity is achieved when the three components (cPGES, casein kinase II and Hsp90) are mixed at a molar proportion of 1:1:1
-
interleukin 1beta
Interleukin-1beta
-
-
-
lipopolysaccharide
-
lipopolysaccharide binds to receptor TLR4 on osteoblasts that directly induces isoform mPGES-1 expression for prostaglandin E2 synthesis, leading to subsequent bone resorption
LPS
-
-
-
n-dodecylmaltoside
-
0.3 mM, 5fold activation
n-octylglucoside
-
34 mM, 3.3fold activation
thiol reagents
-
-
TNF-alpha
-
-
-
TNF-beta
-
-
-
TNFalpha
-
-
-
Triton X-100
-
5 mM, 4.6fold activation
Tumor necrosis factor alpha
-
increase in protein expression and activity of isoform mPGES-1, accompanied by increased COX-2 expression and production of prostaglandin E2
-
additional information
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.13 - 1.61
(5Z,13E)-(15S)-9a,11a-epidioxy-15-hydroxyprosta-5,13-dienoate
0.0024 - 0.16
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
0.6 - 0.75
glutathione
0.05
Prostaglandin G1
-
-
0.16
prostaglandin G2
-
-
0.01
Prostaglandin H1
-
-
0.0149 - 0.5345
prostaglandin H2
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
7 - 50
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
21
glutathione
Homo sapiens
-
-
75
prostaglandin G2
Homo sapiens
-
-
50
prostaglandin H2
Homo sapiens
-
-
75
prostaglandine G2
Homo sapiens
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0035
(2E)-2-(2,5-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]benzylidene)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
(2E)-2-(2,5-bis[[4-(trifluoromethyl)benzyl]oxy]benzylidene)hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0034
(2E)-2-[2,5-bis(2-cyclohexylethoxy)benzylidene]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0015
(2E)-2-[2,5-bis(2-phenylethoxy)benzylidene]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
(2E)-2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzylidene]hexanoic acid
0.0042
(2R)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0046
(2S)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0051
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(5,8-dihydronaphthalen-1-yl)acetic acid
Homo sapiens
-
-
0.01
([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)acetic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.03
1-[2-(2-methylphenyl)ethyl]-4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazole
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.000012
1-[4-[2-(2-carboxy-2-methylpropyl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-4-yl]-2-fluorophenyl]pyridinium
Homo sapiens
-
-
0.0003
15-deoxy-DELTA12,14-prostaglandin J2
Homo sapiens
-
-
0.0022
2(4-(3-biphenyloxypropoxy)phenylthio)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0011
2-(2,3-diphenethoxybenzylidene)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.00066
2-(2-chloro-6-fluorophenyl)-4-(4-chlorophenyl)-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.00032
2-(2-chloro-6-fluorophenyl)-4-(4-phenoxyphenyl)-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.00015
2-(2-chloro-6-fluorophenyl)-4-[4-(2-phenylethyl)phenyl]-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylethynyl)phenyl]-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.00018
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.0014
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfonyl)phenyl]-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.000035
2-(2-chloro-6-fluorophenyl)-4-[4-[(E)-2-phenylethenyl]phenyl]-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.0024
2-(3,5-diphenethoxybenzyl)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0028
2-(3,5-diphenethoxybenzylidene)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0037
2-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
Homo sapiens
-
-
0.0059
2-([4,6-bis[2-(4-cyanophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-([4,6-bis[2-(4-methoxyphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0009
2-([4,6-bis[2-(4-methylphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0037
2-([4,6-bis[2-(4-nitrophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0065
2-([4,6-bis[2-(thiophen-3-yl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0039
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
Homo sapiens
-
-
0.0017
2-([4-chloro-6-[(4'-cyanobiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
Homo sapiens
-
-
0.0021
2-([4-chloro-6-[(5-methoxy-2-methylbiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
Homo sapiens
-
-
0.0013
2-([4-[(biphenyl-4-ylmethyl)amino]-6-chloropyrimidin-2-yl]sulfanyl)nonanoic acid
Homo sapiens
-
-
0.0029
2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.01
2-([4-[3-(2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0088
2-([4-[3-(2-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.01
2-([4-[3-(3-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
0.0094
2-([4-[3-(4-chloro-2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0093
2-([4-[3-(4-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0022
2-([4-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.01
2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.000058 - 0.00059
2-chloro-N-[3-(naphthalen-1-ylcarbamoyl)phenyl]benzamide
0.0046
2-[(3,5-diphenethoxyphenyl)thio]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[(4,6-bis[2-[4-(trifluoromethoxy)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0019
2-[(4,6-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0012
2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0041
2-[(4-[3-[2-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0027
2-[(4-[3-[3-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.002
2-[(4-[3-[3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0017
2-[(4-[3-[4-chloro-3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0026
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]nonanoic acid
Homo sapiens
-
-
0.0039
2-[2,3-bis(2-phenylethoxy)benzyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[2,4-bis(2-phenylethoxy)benzyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0024
2-[2,5-bis(2-phenylethoxy)benzyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.00018
2-[2-(2-chloro-6-fluorophenyl)-4-[6-(phenylethynyl)pyridin-3-yl]-1H-imidazol-5-yl]ethanol
Homo sapiens
-
pH and temperature not specified in the publication
0.0027
2-[3,4-bis(2-phenylethoxy)benzyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0006
2-[3,5-bis(2-phenylethoxy)phenoxy]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[3-(aminooxy)-2,2-dimethyl-3-oxopropyl]-3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indole
Homo sapiens
-
IC50: 0.01 mM
0.0014
2-[4-(4-bromophenyl)-1H-imidazol-2-yl]benzonitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.001
2-[4-(4-chlorophenyl)-1H-imidazol-2-yl]-3-fluorobenzonitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.005
2-[4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)phenyl]propan-2-ol
Homo sapiens
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.0071
2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzyl]hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0000009
2-[6-(2-cyclopropylethoxy)-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
Homo sapiens
-
-
0.006
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid
Homo sapiens
-
-
0.0000009
2-[6-bromo-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
0.0000007
2-[6-chloro-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
Homo sapiens
-
-
0.01
2-[[4,6-bis(2-cycloheptylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0024
2-[[4,6-bis(2-cyclohexylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[[4,6-bis(2-cyclopentylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0096
2-[[4,6-bis(2-cyclopropylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0073
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]butanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.002
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]octanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[[4,6-bis(3-methylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0022
2-[[4,6-bis(3-phenylpropoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0009
2-[[4,6-bis(4-phenylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0038
2-[[4,6-bis(benzyloxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[[4-(3-phenoxypropoxy)phenyl]sulfanyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0016
2-[[4-(biphenyl-4-ylamino)-6-chloropyrimidin-2-yl]sulfanyl]nonanoic acid
Homo sapiens
-
-
0.00323
3,4-bis-(3-benzo[b]thiophen-3-yl-phenyl)-5-hydroxy-5H-furan-2-one
Mus musculus
Q9JM51
-
0.0018
3-(1-benzothiophen-2-yl)-2-bromo-5-hydroxycyclopent-2-en-1-one
Homo sapiens
-
-
0.00011
3-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazole
Homo sapiens
-
pH and temperature not specified in the publication
0.0021
3-(naphthalen-1-ylamino)-6-nitrobenzo[d]isothiazole 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.002
3-benzamidocarbazole
Homo sapiens
-
-
0.00224
3-bromo-4-(4'-butyl-biphenyl-4-yl)-5-hydroxy-5H-furan-2-one
Mus musculus
Q9JM51
-
0.00361
3-bromo-5-hydroxy-4-[1,1':4',1'']terphenyl-4-yl-5H-furan-2-one
Mus musculus
Q9JM51
-
0.00029
3-[(5E)-3-(4-butylbenzyl)-1-(4-chlorobenzyl)-4-methylidene-5-[(2E)-4-methylpent-2-en-1-ylidene]-4,5-dihydro-1H-pyrrol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00029 mM
0.00025
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
0.0032
3-[1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0032 mM
0.0011
3-[1-(4-chlorobenzyl)-3-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0011 mM
0.0006
3-[1-(4-chlorobenzyl)-3-methyl-5-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00060 mM
0.0043
3-[1-(4-chlorobenzyl)-3-methyl-7-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0043 mM
0.002
3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000004
3-[1-(4-chlorobenzyl)-4-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000008
3-[1-(4-chlorobenzyl)-4-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000022
3-[1-(4-chlorobenzyl)-4-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000005
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000003
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000007
3-[1-(4-chlorobenzyl)-4-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.00065
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenoxy-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00065 mM
0.0064
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0064 mM
0.0009
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-[(2-methylphenyl)carbonyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00090 mM
0.000004
3-[1-(4-chlorobenzyl)-5-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000004 mM
0.000008
3-[1-(4-chlorobenzyl)-5-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000008 mM
0.000022
3-[1-(4-chlorobenzyl)-5-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000022 mM
0.000005
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000005 mM
0.000003
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000003 mM
0.000033
3-[1-(4-chlorobenzyl)-5-(2-fluoro-3'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000033 mM
0.000031
3-[1-(4-chlorobenzyl)-5-(2-fluoro-4'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000031 mM
0.000007
3-[1-(4-chlorobenzyl)-5-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000007 mM
0.000012
3-[1-(4-chlorobenzyl)-5-(3-fluoro-4-pyridin-3-ylphenyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000012 mM
0.0026
3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0026 mM
0.000006
3-[1-(4-chlorobenzyl)-5-[2-fluoro-2'-(phenylcarbonyl)biphenyl-4-yl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000006 mM
0.000032
3-[1-(4-chlorobenzyl)-5-[3-fluoro-4-(pyrimidin-5-ylmethyl)phenyl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000032 mM
0.0016
3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
i.e. 3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid or FLAP, formerly designated L-663,536, a lipoxygenase inhibitor, IC50: 0.0016 mM
0.00006
3-[3-(benzylsulfanyl)-1-(4-chlorobenzyl)-5-[4-[(4-chloro-2-fluorophenyl)ethynyl]phenyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.0021
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.0024
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.01
3-[3-(tert-butylsulfanyl)-1-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.01 mM
0.0032
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-(3-phenylpropyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0032 mM
0.0067
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-prop-2-en-1-yl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0067 mM
0.01
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.01 mM
0.00026
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
0.000006
3-[4-(2'-acetyl-2-fluorobiphenyl-4-yl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000016
3-[4-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.01
3-[4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]propanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.00016
3-[5-biphenyl-3-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00016 mM
0.000016
3-[5-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000016 mM
0.00033
3-[5-tert-butyl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00033 mM
0.03
4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
0.00459
4-(4'-butyl-biphenyl-4-yl)-3-(4-butyl-phenyl)-5-hydroxy-5H-furan-2-one
Mus musculus
Q9JM51
-
0.03
4-(4'-phenoxybiphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.00057
4-(4-benzylphenyl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.00039
4-(4-chlorobenzyl)-2,6-bis[4-(trifluoromethoxy)phenyl]-4H-thieno[3,2-b]pyrrole
Homo sapiens
-
-
0.00011
4-(biphenyl-4-yl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.005
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzamide
0.03
4-[(4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazol-1-yl)sulfonyl]benzoic acid
0.0032
4-[[4-(biphenyl-4-yl)-1H-1,2,3-triazol-1-yl]methyl]-3-nitrobenzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.03
5-(4-bromophenyl)-3-(2-chloro-6-fluorophenyl)-1,2,4-oxadiazole
0.00084
5-hydroxy-3-naphthalen-2-yl-4-(3-naphthalen-2-yl-phenyl)-5H-furan-2-one
Mus musculus
Q9JM51
-
0.00094
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(1,3-thiazol-2-ylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000013
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohex-1-en-1-ylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000033
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohexylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.00017
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclopropylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000023
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.00048
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(pyridin-3-ylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.0025
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-ethynylpyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000009
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(2-chlorophenyl)ethynyl]pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000004
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(3-chlorophenyl)ethynyl]pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000031
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(4-chlorophenyl)ethynyl]pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.00002
5-[2-(2-chloro-6-fluorophenyl)-5-methyl-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000016
5-[5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-(phenylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
5-[5-bromo-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000005
5-[5-chloro-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.0067
6-nitro-3-(m-tolylamino) benzo[d]isothiazole 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0236
6-nitro-N-phenyl-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
6-nitro-N-[3-(propan-2-yl)phenyl]-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0011
7-hydroxy-N,N'-bis(2,4,6-trimethylphenyl)naphthalene-1,3-disulfonamide
Homo sapiens
-
-
0.044
acetaminophen
Homo sapiens
-
-
0.005
aminomethyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
Homo sapiens
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.0003
arachidonic acid
Homo sapiens
-
-
0.0018
benzothiophene gamma-hydroxybutenolide
Mus musculus
Q9JM51
-
0.0000008
biarylimidazole
Homo sapiens
-
-
0.0012
cysteinyl leukotriene LTC4
Homo sapiens
-
-
0.0003
deoxy-prostaglandin J2
Homo sapiens
-
IC50: 0.0003 mM
0.23
dyphylline
Homo sapiens
-
-
0.0003
eicosapentaenoic acid
Homo sapiens
-
-
0.01
ethyl 2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoate
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0056
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]nonanoate
Homo sapiens
-
-
0.0072
methyl 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoate
Homo sapiens
-
IC50: 0.0072 mM
0.005
methyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
Homo sapiens
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.0000017
methyl 4-[6-bromo-2-(2-chloro-6-fluorophenyl)-1H-phenanthro[9,10-d]imidazol-9-yl]but-3-ynoate
Homo sapiens
-
-
0.000003
MF63
Homo sapiens
-
pH and temperature not specified in the publication
0.0016 - 0.0032
MK-886
0.0024
MK886
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.05
N-(1,3-benzodioxol-4-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
0.0073
N-(3-bromophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0057
N-(3-chlorophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0088
N-(3-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
N-(3-tert-butylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0169
N-(4-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
N-(5-bromonaphthalen-1-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.00015
N-(6-nitro-1,1-dioxido-1,2-benzothiazol-3-yl)quinolin-5-amine
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
N-(biphenyl-3-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0013
N-[4-chloro-3-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-2-(trifluoromethyl)benzamide
Homo sapiens
-
-
0.01 - 0.02
NS-398
0.11
Oxacillin
Homo sapiens
-
-
0.0000165 - 0.00108
PF-9184
0.08
sulindac
0.03
[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]methyl benzoate
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.0012
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl](phenyl)acetic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]acetic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.04
-
substrate 15-hydroperoxy-prostaglandin E2
0.043
-
substrate 5-hydroperoxyeicostetraenoic
0.054
-
mutant enzyme T131V/L135F/A138F, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4C
0.059
-
wild type enzyme, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4C
0.086
-
mutant enzyme V131T/F135L/F138A, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4C
0.17
-
substrate cumene hydroperoxide
0.214
-
wild type enzyme, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4C
0.81
-
substrate 1-chloro-2,4-dinitrobenzene
1.6
-
prostaglandin H1
1.8
-
prostaglandin H2
2.2
-
cPGES plus casein kinase II
2.5
-
cPGES plus casein kinase II plus Hsp90
100 - 200
-
in the presence of 0.4 mM prostaglandin H2 or prostaglandin G2 and 2.5 mM glutatione
120
-
substrate (5Z,13E)-(15S)-9a,11a-epidioxy-15-hydroxyprosta-5,13-dienoate
190
-
substrate prostaglandin G2
510
-
in the presence of 10 microM prostaglandin H2 or prostaglandin G2 and 2.5 mM glutatione
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5.5 - 7
-
-
6 - 7
-
GSH-dependent enzyme from deferent duct
6 - 8
-
GSH-independent enzyme from heart
6.2
-
IgG1(hei-26)-reactive protein
6.5
-
enzyme assay
6.5 - 7.5
-
IgG1(hei-7)-reactive protein
7 - 8
-
-
8
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5 - 10
-
pH 5: about 75% of maximal activity, pH 10: about 70% of maximal activity, GSH-dependent enzyme from deferent duct
5 - 12
-
pH 5: about 60% of maximal activity, pH 9: about 75% of maximal activity, pH 12: about 90% of maximal activity, GSH-independent enzyme from heart
5.5 - 9.5
-
almost inactive below pH 5.5 and above pH 9.5
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
20
-
activity assay at room temperature
22
-
assay at room temperature
25
-
assay at
additional information
-
microsomal suspension is incubated on ice with PGH2, enzyme activity assay
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
50
-
PGE synthase activity is completely lost at 50C for 5 min
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
low expression of mPEGS-2 in the urothelium
Manually annotated by BRENDA team
-
in normal breast the enzyme is seen in myoepithelial cells and in stromal fibroblasts and vascular smooth muscle, in breast disease, the enzyme is observed in epithelial cells adjacent to cancer, in scattered foci of fibrocystic disease, in ductal carcinoma in situ and in invasive cancers, in addition to myoepithelial cells
Manually annotated by BRENDA team
-
colocalized with cyclooxygenase-2
Manually annotated by BRENDA team
-
osteoarthritic chondrocyte
Manually annotated by BRENDA team
-
extravillous cytotrophoblast is strongly posistive for enzyme protein in the basal plate
Manually annotated by BRENDA team
-
follicular dendritic cell
Manually annotated by BRENDA team
-
middle frontal gyrus tissue
Manually annotated by BRENDA team
intermediate abundance of the protein
Manually annotated by BRENDA team
expression of the primary form of PGES, mPGES-1
Manually annotated by BRENDA team
-
lowest protein expression
Manually annotated by BRENDA team
-
mesenchymal cells of the basal layer, co-localization of isoform mPGES-1 and COX-2 after induction of oesophagitis
Manually annotated by BRENDA team
-
peripheral blood monocyte, no basal expression of enzyme, but strong induction of expression by proinflammatory stimulation via LPS. In alternatively activated M2 monocytes-macrophages, interleukins IL-4, IL-13, and to a lesser extent, IL-10 or interferon IFN-gamma inhibit LPS-induced expression of enzyme. Induction of enzyme expression correlates with changes at the protein level and production of prostaglandin E2
Manually annotated by BRENDA team
-
; faint expression levels
Manually annotated by BRENDA team
-
mPEGS-2
Manually annotated by BRENDA team
-
only isoform mPGES-1 can be found in neutrophils, it co-localizes with COX-2 and its expression is mainly constitutive
Manually annotated by BRENDA team
at 24 h after fertilization, endothelial cells of the pharyngeal arch vasculature
Manually annotated by BRENDA team
-
pulmonary epithelial cell
Manually annotated by BRENDA team
-
high expression of mPEGS-2
Manually annotated by BRENDA team
-
mPEGS-2
Manually annotated by BRENDA team
-
lowest protein expression
Manually annotated by BRENDA team
-
normal and psoriatic
Manually annotated by BRENDA team
-
mPEGS-2
Manually annotated by BRENDA team
-
enzyme protein is prominent in vesicles separating from syncytiotrophoblast into the intervillous space
Manually annotated by BRENDA team
-
placental trophoblast
Manually annotated by BRENDA team
-
constitutive expression of enzyme is associated with increased prostaglandin E2 production and stimulation of growth. Inhibition of enzyme activity and expression block the release of prostaglandin E2 and decrease cellular proliferation. Antiproliferative effects may be overcome by exogenous prostaglandin E2
Manually annotated by BRENDA team
-
low expression of mPEGS-2
Manually annotated by BRENDA team
-
expression of cPEGS, mPEGS-2, and mPEGS-1
Manually annotated by BRENDA team
-
enzyme protein is elevated in the endometrium during spontaneous term labour and after estradiol treatment. Enzyme is localized to endometrial stromal cells
Manually annotated by BRENDA team
-
cells express both microsomal isoforms mPGES-1 and mPGES-2 and cytosolic isoform cPGES; cells express both microsomal isoforms mPGES-1 and mPGES-2 and cytosolic isoform cPGES. Isoform mPGES-1 contributes most to total activity and is induced by interleukin IL-1beta, which in turn reduces the ability of cells to produce prostaglandin I2
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
additional information
-
cPGES is directly associated with and phosphorylated by casein kinase 2, cPGES, casein kinase 2 and Hsp90 form a stoichiometric complex of 1:1:1 immediately after cell activation, Hsp90 acts as an essential scaffold protein that brings cPGES and casein kinase 2 in proximity, thereby allowing their efficient functional interaction under physiological condition
-
Manually annotated by BRENDA team